[1]
|
Press, R.H., Zhang, C., et al. (2018) Targeted Sequencing and Intracranial Outcomes of Patients with Lung Adenocarcinoma Brain Metastases Treated with Radiotherapy. Cancer, 124, 3586-3595. https://doi.org/10.1002/cncr.31589
|
[2]
|
Tsakonas, G., De Petris, L. and Ekman, S. (2017) Management of Brain Metastasized Non-Small Cell Lung Cancer (NSCLC) from Local Treatment to New Systemic Therapies. Cancer Treatment Reviews, 54, 122-131.
https://doi.org/10.1016/j.ctrv.2017.02.004
|
[3]
|
Schuler, M., Wu, Y.L., Hirsh, V., et al. (2016) First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology, 11, 380-390. https://doi.org/10.1016/j.jtho.2015.11.014
|
[4]
|
Cai, Y., Wang, J.Y. and Liu, H. (2013) Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-Small Cell Lung Cancer Patients with Chemotherapy Failure. Asian Pacific Journal of Cancer Prevention, 14, 5699-5703. https://doi.org/10.7314/APJCP.2013.14.10.5699
|
[5]
|
Kretowska, M. (2018) Tree-Based Models for Survival Data with Competing Risks. Computer Methods & Programs in Biomedicine, 159, 185-198. https://doi.org/10.1016/j.cmpb.2018.03.017
|
[6]
|
Magnuson, W.J., Lester-Coll, N.H., Wu, A.J., et al. (2017) Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 35, 1070-1077. https://doi.org/10.1200/JCO.2016.69.7144
|
[7]
|
Shin, D.Y., Na, I.I., Kim, C.H., et al. (2014) EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas. Journal of Thoracic Oncology, 9, 195-199. https://doi.org/10.1097/JTO.0000000000000069
|
[8]
|
Gow, C.H., Chien, C.R., Chang, Y.L., et al. (2008) Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response. Clinical Cancer Research, 14, 162-168. https://doi.org/10.1158/1078-0432.CCR-07-1468
|
[9]
|
张矛, 陈忠民, 崔洪霞, 孙涛. 非小细胞肺癌脑预防照射研究进展[J]. 中华肺部疾病杂志(电子版), 2016, 9(6): 666-670.
|
[10]
|
Wang, X., Ye, X., Tang, W., et al. (2018) Efficacy and Safety of Radiotherapy plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data. Translational Oncology, 11, 1119-1127.
https://doi.org/10.1016/j.tranon.2018.07.003
|
[11]
|
Franzoi, M.A. and Hortobagyi, G.N. (2019) Leptomeningeal Carcinomatosis in Patients with Breast Cancer. Critical Reviews in Oncology/Hematology, 135, 85-94. https://doi.org/10.1016/j.critrevonc.2019.01.020
|
[12]
|
Barnholtzsloan, J.S., Sloan, A.E., Davis, F.G., et al. (2004) Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 22, 2865-2872. https://doi.org/10.1200/JCO.2004.12.149
|
[13]
|
Gore, E.M., Bae, K., Wong, S.J., et al. (2011) Phase III Comparison of Prophylactic Cranial Irradiation versus Observation in Patients with Locally Advanced Non-Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 272-278. https://doi.org/10.1200/JCO.2010.29.1609
|
[14]
|
Jonnalagadda, S., Arcinega, J., Smith, C., et al. (2011) Validation of the Lymph Node Ratio as a Prognostic Factor in Patients with N1 Non-Small Cell Lung Cancer. Cancer, 117, 4724-4731. https://doi.org/10.1002/cncr.26093
|
[15]
|
Wang, S.Y., Ye, X., Ou, W., et al. (2009) Risk of Cerebral Metastases for Postoperative Locally Advanced Non-Small-Cell Lung Cancer. Lung Cancer, 64, 238-243. https://doi.org/10.1016/j.lungcan.2008.08.012
|
[16]
|
刘宇, 张幸平, 刘辉, 等. 非小细胞肺癌脑转移放射治疗预后因素分析[J]. 中华肿瘤防治杂志, 2014, 21(21): 1719-1722.
|
[17]
|
Mujoomdar, A., Austin, J.H.M., Malhotra, R., et al. (2007) Clinical Predictors of Metastatic Disease to the Brain from Non-Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases. Radiology, 243, 882-888.
https://doi.org/10.1148/radiol.2423051707
|
[18]
|
Iuchi, T., et al. (2015) Frequency of Brain Metastases in Non-Small-Cell Lung Cancer, and Their Association with Epidermal Growth Factor Receptor Mutations. International Journal of Clinical Oncology, 20, 674-679.
https://doi.org/10.1007/s10147-014-0760-9
|
[19]
|
Lee, D.W., Shin, D.Y., Kim, J.W., et al. (2014) Additional Prognostic Role of EGFR Activating Mutations in Lung Adenocarcinoma Patients with Brain Metastasis: Integrating with Lung Specific GPA Score. Lung Cancer, 86, 363-368.
https://doi.org/10.1016/j.lungcan.2014.10.001
|
[20]
|
Stani, K., Zwitter, M., Turnsek Hitij, N., et al. (2014) Brain Metastases in Lung Adenocarcinoma: Impact of EGFR Mutation Status on Incidence and Survival. Radiology and Oncology, 48, 173-183.
https://doi.org/10.2478/raon-2014-0016
|
[21]
|
Zhang, Z.H., Geskus, R.B., Kattan, M.W., Zhang, H.Y., Liu, T.Y., et al. (2017) Nomogram for Survival Analysis in the Presence of Competing Risks. Annals of Translational Medicine, 5, 403. https://doi.org/10.21037/atm.2017.07.27
|
[22]
|
Veena, M., Siwar, A., Gordon, G., et al. (2017) Criteria for Use of Composite End Points for Competing Risks: A Systematic Survey of the Literature with Recommendations. Journal of Clinical Epidemiology, 82, 4-11.
https://doi.org/10.1016/j.jclinepi.2016.12.001
|
[23]
|
Zhou, H.Q. and Zhang, Y.X. (2018) Nomogram to Predict Cause-Specific Mortality in Patients with Surgically Resected Stage I Non-Small-Cell Lung Cancer: A Competing Risk Analysis. Clinical Lung Cancer, 19, e195-e203.
https://doi.org/10.1016/j.cllc.2017.10.016
|